Direclidine vs Emraclidine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline

Direclidine

Developed by Neurocrine Biosciences under a licence from Nxera Pharma

Phase 3 in Schizophreniasmall molecule
Partial signal

NCT05545111 · Phase 2 · completed

The study randomly assigned 210 participants to four NBI-1117568 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: October 2027 · NCT06963034 (registry estimate)

Reported efficacy

Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6 (Baseline and Week 6): PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline (met)

Result source: NCT05545111

Emraclidine

Developed by AbbVie and partners

Phase 2 in Schizophreniasmall molecule
Partial signal

NCT05227703 · Phase 2 · completed

Participants were randomly assigned to emraclidine 15 mg, emraclidine 30 mg, or matching placebo and were double-blinded, with 130–131 participants per group. The primary clinical endpoint was not met: the Week 6 PANSS comparison was nonsignificant for both 15 mg versus placebo (p=0.2925) and 30 mg versus placebo (p=0.3914).

Next expected readout: February 2028 · NCT07145918 (registry estimate)

Reported efficacy

Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) (missed)

Result source: NCT05227703

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDireclidineEmraclidine
PANSS total, change—Trial running · NCT06963034-14.2 vs -16.1+1.9 vs placebo30mg QD · wk 6 · n 96NCT05227703
27 other results
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 93 · Phase 2 · primary NCT05227690
  • -18.5 vs -16.1 15mg QD · wk 6 · n 94 · Phase 2 · primary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 90 · Phase 2 · primary NCT05227690
  • -14.2 vs -16.1 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -12.9 vs -14.7 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.2 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -12 vs -12.8 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -13.3 vs -12.1 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -10 vs -11.2 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -11.3 vs -10.3 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -7.5 vs -8.5 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -9 vs -8.7 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -4.9 vs -5 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -6.2 vs -5.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -18.5 vs -16.1 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -16.5 vs -14.7 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -13.4 vs -12.8 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -12.5 vs -11.2 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -8.7 vs -8.5 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -6.8 vs -5 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -14 vs -13.2 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -12.8 vs -12.1 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -10 vs -10.3 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -8.8 vs -8.7 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -5.7 vs -5.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690
CGI-S, change—Trial running · NCT06963034-0.8 vs -0.8±0 vs placebo30 mg QD · wk 6 · n 96NCT05227703
27 other results
  • -0.8 vs -0.8 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 93 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -0.7 vs -0.8 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.5 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.6 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -0.5 vs -0.5 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.4 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -0.2 vs -0.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 94 · Phase 2 · secondary NCT05227703
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -0.9 vs -0.8 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -0.6 vs -0.6 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -0.4 vs -0.4 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.2 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 90 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.5 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.5 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690
PANSS response—Trial running · NCT06963034—Not reported
PSP, change—Trial running · NCT06963034—Not reported
Relapse (% of patients)—Trial running · NCT06963034—Not reported

PANSS total, change

Direclidine
—Trial running · NCT06963034
Emraclidine
-14.2 vs -16.1+1.9 vs placebo30mg QD · wk 6 · n 96NCT05227703
27 other results
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 93 · Phase 2 · primary NCT05227690
  • -18.5 vs -16.1 15mg QD · wk 6 · n 94 · Phase 2 · primary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 90 · Phase 2 · primary NCT05227690
  • -14.2 vs -16.1 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -12.9 vs -14.7 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.2 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -12 vs -12.8 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -13.3 vs -12.1 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -10 vs -11.2 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -11.3 vs -10.3 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -7.5 vs -8.5 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -9 vs -8.7 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -4.9 vs -5 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -6.2 vs -5.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -18.5 vs -16.1 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -16.5 vs -14.7 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -13.4 vs -12.8 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -12.5 vs -11.2 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -8.7 vs -8.5 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -6.8 vs -5 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -14 vs -13.2 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -12.8 vs -12.1 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -10 vs -10.3 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -8.8 vs -8.7 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -5.7 vs -5.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690

CGI-S, change

Direclidine
—Trial running · NCT06963034
Emraclidine
-0.8 vs -0.8±0 vs placebo30 mg QD · wk 6 · n 96NCT05227703
27 other results
  • -0.8 vs -0.8 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 93 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -0.7 vs -0.8 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.5 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.6 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -0.5 vs -0.5 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.4 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -0.2 vs -0.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 94 · Phase 2 · secondary NCT05227703
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -0.9 vs -0.8 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -0.6 vs -0.6 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -0.4 vs -0.4 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.2 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 90 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.5 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.5 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690

PANSS response

Direclidine
—Trial running · NCT06963034
Emraclidine
—Not reported

PSP, change

Direclidine
—Trial running · NCT06963034
Emraclidine
—Not reported

Relapse (% of patients)

Direclidine
—Trial running · NCT06963034
Emraclidine
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Direclidine
PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline NCT05545111 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Direclidine: 0 of 4 rows · Emraclidine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmraclidine
Dropout rate
29%30 mg QDa
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 5 more results
—30mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
28.5%15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
—15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
28.7%30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
30.5%10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%30 mg QDa
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 5 more results
—30mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
4.6%15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
—15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
7.8%30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
4.7%10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
Serious AEs
—30 mg QDa
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 5 more results
0.8%30mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
—15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
2.3%15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
0.8%30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
3.1%10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
30mg QDa
headache 13% (placebo 10.8%)
dry mouth 5.3% (placebo 0.8%)
anxiety 3.1% (placebo 3.1%)
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 3 more results
15mg QD
headache 13.8% (placebo 10.8%)
weight increased 8.5% (placebo 3.8%)
constipation 4.6% (placebo 1.5%)
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
30 mg once daily
headache 13.2% (placebo 9.4%)
dry mouth 9.3% (placebo 2.3%)
dyspepsia 7.8% (placebo 3.1%)
NCT05227690 · Phase 2 · registry result, not featured evidence
10 mg once daily
weight increased 17.2% (placebo 8.6%)
headache 14.1% (placebo 9.4%)
somnolence 7% (placebo 4.7%)
NCT05227690 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Emraclidine

PANSS Total -14.2 vs -16.1 placebo score @ 6wk30mg QD
absolute change · score
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 27 more results
-4.9 vs -5 placebo score @ 1wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-7.5 vs -8.5 placebo score @ 2wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-10 vs -11.2 placebo score @ 3wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-12 vs -12.8 placebo score @ 4wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-12.9 vs -14.7 placebo score @ 5wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-14.2 vs -16.1 placebo score @ 6wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-16.5 vs -13.5 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-6.2 vs -5.2 placebo score @ 1wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-9 vs -8.7 placebo score @ 2wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-11.3 vs -10.3 placebo score @ 3wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-13.3 vs -12.1 placebo score @ 4wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-14.7 vs -13.2 placebo score @ 5wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-16.5 vs -13.5 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-18.5 vs -16.1 placebo score @ 6wk15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-6.8 vs -5 placebo score @ 1wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-8.7 vs -8.5 placebo score @ 2wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-12.5 vs -11.2 placebo score @ 3wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-13.4 vs -12.8 placebo score @ 4wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-16.5 vs -14.7 placebo score @ 5wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-18.5 vs -16.1 placebo score @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-14.7 vs -13.5 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-5.7 vs -5.2 placebo score @ 1wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-8.8 vs -8.7 placebo score @ 2wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-10 vs -10.3 placebo score @ 3wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-12.8 vs -12.1 placebo score @ 4wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-14 vs -13.2 placebo score @ 5wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-14.7 vs -13.5 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
CGI-S -0.8 vs -0.83 placebo score @ 6wk30 mg QD
absolute change · score
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 27 more results
-0.21 vs -0.21 placebo score @ 1wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.38 vs -0.42 placebo score @ 2wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.49 vs -0.55 placebo score @ 3wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.62 vs -0.72 placebo score @ 4wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.69 vs -0.78 placebo score @ 5wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.8 vs -0.83 placebo score @ 6wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.84 vs -0.7 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.18 placebo score @ 1wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.35 vs -0.36 placebo score @ 2wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.52 vs -0.48 placebo score @ 3wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.7 vs -0.54 placebo score @ 4wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.74 vs -0.67 placebo score @ 5wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.84 vs -0.7 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-1.05 vs -0.83 placebo score @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.33 vs -0.21 placebo score @ 1wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.42 vs -0.42 placebo score @ 2wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.64 vs -0.55 placebo score @ 3wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.74 vs -0.72 placebo score @ 4wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.91 vs -0.78 placebo score @ 5wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-1.05 vs -0.83 placebo score @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.75 vs -0.7 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.17 vs -0.18 placebo score @ 1wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.39 vs -0.36 placebo score @ 2wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.42 vs -0.48 placebo score @ 3wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.53 vs -0.54 placebo score @ 4wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.64 vs -0.67 placebo score @ 5wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.75 vs -0.7 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
PANSS 30% 12.2% (n=123) vs 19.5% (n=128) placebo @ 6wk30 mg QD
responder rate · % of participants
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 3 more results
17.3% (n=127) vs 10.2% (n=127) placebo @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
23.8% (n=122) vs 19.5% (n=128) placebo @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
17.6% (n=125) vs 10.2% (n=127) placebo @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Direclidine's landscape · Emraclidine's landscape